Aligos Therapeutics, Inc. SEC filings ALGS
Aligos Therapeutics, Inc. has 348 filings in SEC EDGAR's recent list, going back to Jan 16, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 6, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 6, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 6, 2026 | — |
| S-8 | Employee stock plan registration | Mar 5, 2026 | — |
| S-8 | Employee stock plan registration | Aug 6, 2025 | — |
| 424B3 | Prospectus | Apr 3, 2025 | — |
| S-3 | Shelf registration | Mar 27, 2025 | — |
| S-8 | Employee stock plan registration | Mar 10, 2025 | — |
| S-8 | Employee stock plan registration | Nov 6, 2024 | — |
| S-3 | Shelf registration | Nov 6, 2024 | — |
| S-8 | Employee stock plan registration | Mar 12, 2024 | — |
| 424B3 | Prospectus | Nov 28, 2023 | — |
| S-3 | Shelf registration | Nov 17, 2023 | — |
| S-8 | Employee stock plan registration | Mar 9, 2023 | — |
| S-8 | Employee stock plan registration | Mar 10, 2022 | — |
| S-3 | Shelf registration | Nov 4, 2021 | — |
| 424B4 | Prospectus | Jul 1, 2021 | — |
| S-1 | Registration statement | Jun 28, 2021 | — |
| S-8 | Employee stock plan registration | Mar 23, 2021 | — |
| S-8 | Employee stock plan registration | Oct 20, 2020 | — |
| 424B4 | Prospectus | Oct 19, 2020 | — |
| S-1/A | Amended registration statement | Oct 9, 2020 | — |
| S-1 | Registration statement | Sep 25, 2020 | — |
Showing 21 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ALGS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1799448
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.